Concerto Biosciences
Concerto Biosciences: Revolutionizing microbe interaction analysis with high-tech, ultra-high throughput platform.
Founded
2020Concerto Biosciences: Revolutionizing microbe interaction analysis with high-tech, ultra-high throughput platform.
Concerto Biosciences, founded in Cambridge, MA, is dedicated to revolutionizing humanity's relationship with microbes. The company's core mission is to harness microbial ecology to develop transformative products. Utilizing an ultra-high throughput platform, Concerto Biosciences measures how microbes interact with each other, enabling the creation of innovative microbial products. Their market focus includes sectors that benefit from advanced microbial analysis and product development, such as healthcare, agriculture, and biotechnology.
Notable affiliated people and investors include experts in microbiology and biotechnology, though specific names are not provided. Key achievements for Concerto Biosciences include the development of their high-tech microbe analysis platform, which has set new standards in experimental rigor for microbial product discovery. The overall impact of Concerto Biosciences lies in its potential to create groundbreaking microbial solutions that can address critical challenges in various industries, ultimately enhancing human health and environmental sustainability.
Companies similar to Concerto Biosciences include The BioCollective, Wild Microbes, Biomiic and BiomeSense.
Concerto Biosciences was founded in 2020.
Concerto Biosciences' headquarters is located in Cambridge, MA, US.
Concerto Biosciences' most recent funding round was for $24.5M (USD) in March 2022.
As of Mar 22, 2022, Concerto Biosciences has raised a total of $26M (USD).
Concerto Biosciences has 11 employees as of Feb 5, 2024.
Biomiic
